Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 24.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 20.04.23
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
EQS-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Germany
eqs_en 
0 20.04.23
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24067/Sartorius.svg.png
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed
EQS-News: SARTORIUS AG: First quarter of Sartorius characterized by normalization of demand; full-year outlook confirmed
eqs_en 
0 20.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 19.04.23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
eqs_en 
0 19.04.23
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
EQS-News: Gerresheimer AG: Gerresheimer AG successfully completes EUR 271.6 million capital increase
eqs_en 
0 18.04.23
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG issues 3,140,000 million new shares at a placement price of EUR 86.50 per new share
eqs_en 
0 18.04.23
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-News: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
eqs_en 
0 18.04.23
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23715/Gerresheimer_logo.svg.png
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
EQS-Adhoc: Gerresheimer AG: Gerresheimer AG launches cash capital increase with exclusion of shareholders' subscription rights through accelerated bookbuilding by up to 3,140,000 shares
eqs_en 
0 18.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 18.04.23
EQS-News: Newron announces AGM 2023 results  : https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
EQS-News: Newron announces AGM 2023 results  
EQS-News: Newron announces AGM 2023 results  
eqs_en 
0 18.04.23
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023http://www.aevis.com: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/12720/aevis-logo.png
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
AEVIS VICTORIA SA – Ordinary General Meeting of Shareholders on 9 May 2023
eqs_en 
0 18.04.23
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed: https://assets2.sharewise.com/attachment/file/24054/375px-Dr%C3%A4ger_Logo.svg.png
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2023: Strong net sales growth and positive EBIT – forecast for 2023 confirmed
eqs_en 
0 17.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 17.04.23
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
EQS-News: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)
eqs_en 
0 16.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 14.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 13.04.23
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flowhttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow
EQS-News: HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow
eqs_en 
0 13.04.23
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?: https://g.foolcdn.com/editorial/images/727414/pharmacists-looking-at-pills-in-bottle.jpg
Can Axsome Hold Out Till Depression Drug Becomes a Blockbuster?

Axsome Therapeutics' (NASDAQ: AXSM) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over

TheMotleyFool 
0 12.04.23
2 Unstoppable Growth Stocks to Buy While Share Prices Are Low: https://g.foolcdn.com/editorial/images/727549/a-person-looking-at-a-chart-on-their-laptop.jpg
2 Unstoppable Growth Stocks to Buy While Share Prices Are Low

A look at the facts will often reveal businesses that are poised for future growth and/or show no signs of slowing down. The stocks for these types of businesses tend to be particularly valuable to

TheMotleyFool 
0 12.04.23
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 12.04.23
Which Healthcare Company Will Be the First to Get to a $1 Trillion Market Cap?: https://g.foolcdn.com/editorial/images/727540/a-doctor-looking-at-a-tablet-with-another-person.jpg
Which Healthcare Company Will Be the First to Get to a $1 Trillion Market Cap?

There are several healthcare companies with market caps in the hundreds of billions. However, there isn't one among this group that is approaching the $1 trillion mark just yet. There are four

TheMotleyFool 
0 12.04.23
Why 2023 Could Be a Tough Year for AbbVie Stock: https://g.foolcdn.com/editorial/images/727547/a-couple-using-a-laptop-and-reviewing-documents.jpg
Why 2023 Could Be a Tough Year for AbbVie Stock

At first glance, AbbVie (NYSE: ABBV) might look like a stock that's reasonably valued or even a cheap buy. It even has the added bonus of an attractive dividend yield of 3.7%. But there are some

TheMotleyFool 
0 12.04.23
Why Shares of Shockwave Medical Jumped on Tuesday: https://g.foolcdn.com/editorial/images/727902/using-a-stethoscope-listen-to-the-heartbeat-of-patient-1.jpg
Why Shares of Shockwave Medical Jumped on Tuesday

Shares of Shockwave Medical (NASDAQ: SWAV) were up 10.69% early Tuesday afternoon after the Centers for Medicare and Medicaid Services (CMS) unveiled a proposed rule that detailed new payment codes

TheMotleyFool 
0 11.04.23